StockNews.com Upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “Sell”

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research report issued to clients and investors on Tuesday.

A number of other brokerages have also weighed in on ARWR. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, June 11th. The Goldman Sachs Group assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They set a “neutral” rating and a $31.00 target price for the company. Morgan Stanley dropped their target price on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating for the company in a research report on Monday, May 13th. Chardan Capital restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, June 26th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Thursday, June 20th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $47.89.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $25.07 on Tuesday. The firm has a market cap of $3.11 billion, a P/E ratio of -5.90 and a beta of 0.94. Arrowhead Pharmaceuticals has a 1-year low of $20.67 and a 1-year high of $39.83. The company has a 50 day simple moving average of $24.53 and a two-hundred day simple moving average of $28.31.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. Arrowhead Pharmaceuticals’s quarterly revenue was down 100.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.45 earnings per share. Equities analysts anticipate that Arrowhead Pharmaceuticals will post -3.05 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider Tracie Oliver sold 9,394 shares of the stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total transaction of $237,480.32. Following the completion of the transaction, the insider now owns 127,107 shares in the company, valued at $3,213,264.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Tracie Oliver sold 9,394 shares of the stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total value of $237,480.32. Following the sale, the insider now owns 127,107 shares of the company’s stock, valued at $3,213,264.96. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Victoria Vakiener sold 1,799 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the sale, the director now directly owns 30,205 shares in the company, valued at approximately $704,078.55. The disclosure for this sale can be found here. 4.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ARWR. Washington Trust Advisors Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at $25,000. Neo Ivy Capital Management purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $41,000. Quest Partners LLC purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $45,000. Friedenthal Financial purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $51,000. Finally, Headlands Technologies LLC increased its stake in Arrowhead Pharmaceuticals by 7,696.8% in the 1st quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock worth $69,000 after buying an additional 2,386 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.